Capricor Therapeutics Inc - Asset Resilience Ratio
Capricor Therapeutics Inc (CAPR) has an Asset Resilience Ratio of 8.51% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Capricor Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Capricor Therapeutics Inc's Asset Resilience Ratio has changed over time. See Capricor Therapeutics Inc (CAPR) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Capricor Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Capricor Therapeutics Inc (CAPR) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $30.28 Million | 8.51% |
| Total Liquid Assets | $30.28 Million | 8.51% |
Asset Resilience Insights
- Limited Liquidity: Capricor Therapeutics Inc maintains only 8.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Capricor Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Capricor Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Capricor Therapeutics Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Capricor Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.51% | $30.28 Million | $355.95 Million | -73.75pp |
| 2024-12-31 | 82.25% | $140.23 Million | $170.48 Million | +40.04pp |
| 2023-12-31 | 42.21% | $24.79 Million | $58.73 Million | -21.30pp |
| 2022-12-31 | 63.52% | $31.82 Million | $50.09 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $41.33 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $34.62 Million | -- |
| 2019-12-31 | 53.86% | $5.99 Million | $11.11 Million | +21.45pp |
| 2018-12-31 | 32.41% | $3.00 Million | $9.25 Million | -16.65pp |
| 2017-12-31 | 49.07% | $7.98 Million | $16.27 Million | -20.23pp |
| 2016-12-31 | 69.29% | $12.99 Million | $18.75 Million | +19.52pp |
| 2015-12-31 | 49.78% | $8.00 Million | $16.07 Million | +27.94pp |
| 2014-12-31 | 21.84% | $2.98 Million | $13.63 Million | +15.94pp |
| 2013-12-31 | 5.90% | $326.49K | $5.54 Million | -71.41pp |
| 2012-12-31 | 77.31% | $4.19 Million | $5.42 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.37 Million | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more